全文获取类型
收费全文 | 166926篇 |
免费 | 16024篇 |
国内免费 | 7576篇 |
专业分类
耳鼻咽喉 | 2280篇 |
儿科学 | 3878篇 |
妇产科学 | 1827篇 |
基础医学 | 30264篇 |
口腔科学 | 5333篇 |
临床医学 | 12970篇 |
内科学 | 22864篇 |
皮肤病学 | 4434篇 |
神经病学 | 9155篇 |
特种医学 | 3701篇 |
外国民族医学 | 118篇 |
外科学 | 15207篇 |
综合类 | 26029篇 |
现状与发展 | 49篇 |
预防医学 | 4357篇 |
眼科学 | 3469篇 |
药学 | 12885篇 |
25篇 | |
中国医学 | 5132篇 |
肿瘤学 | 26549篇 |
出版年
2024年 | 132篇 |
2023年 | 2372篇 |
2022年 | 2975篇 |
2021年 | 5786篇 |
2020年 | 5430篇 |
2019年 | 5328篇 |
2018年 | 5519篇 |
2017年 | 5779篇 |
2016年 | 6054篇 |
2015年 | 6895篇 |
2014年 | 10023篇 |
2013年 | 11090篇 |
2012年 | 9577篇 |
2011年 | 10714篇 |
2010年 | 8910篇 |
2009年 | 8537篇 |
2008年 | 8994篇 |
2007年 | 9217篇 |
2006年 | 8358篇 |
2005年 | 7679篇 |
2004年 | 6814篇 |
2003年 | 5906篇 |
2002年 | 4853篇 |
2001年 | 4172篇 |
2000年 | 3422篇 |
1999年 | 2976篇 |
1998年 | 2454篇 |
1997年 | 2417篇 |
1996年 | 2093篇 |
1995年 | 2125篇 |
1994年 | 1878篇 |
1993年 | 1565篇 |
1992年 | 1276篇 |
1991年 | 1185篇 |
1990年 | 921篇 |
1989年 | 866篇 |
1988年 | 811篇 |
1987年 | 648篇 |
1986年 | 604篇 |
1985年 | 795篇 |
1984年 | 716篇 |
1983年 | 492篇 |
1982年 | 517篇 |
1981年 | 418篇 |
1980年 | 347篇 |
1979年 | 259篇 |
1978年 | 184篇 |
1977年 | 144篇 |
1976年 | 107篇 |
1975年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
91.
目的:探讨 miR-9 通过靶向 E 盒结合锌指蛋白 2(zinc finger E-box binding homeobox 2,ZEB2)对小细胞肺癌(small cell lung cancer,SCLC)细胞生物学行为的调控作用,分析miR-9在SCLC中的作用及其工作机制。方法:采用qPCR、WB和免疫组化方法检测于2018年2月至2019年11月于河北医科大学第四医院肿瘤内科接受手术治疗的67例SCLC患者癌组织及癌旁组织中ZEB2的表达。采用TargetScan预测miR-9的潜在靶基因并通过双荧光素酶报告基因试验、qPCR和WB法进行验证。CCK-8法、流式细胞术和Transwell实验检测miR-9和ZEB2 过表达对 NCI-H446 的生物学行为影响,WB法检测对细胞中E-cadherin,N-cadherin和Vimentin蛋白表达的影响。利用miR-9过表达NCI-H446细胞构建SCLC裸鼠移植瘤模型,观察miR-9对裸鼠移植瘤生长的影响。结果:SCLC组织中ZEB2的mRNA和蛋白表达水平明显高于癌旁正常组织(P<0.01)。miR-9在ZEB2的3'' UTR上具有潜在的结合位点,与对照组相比,miR-9过表达组NCI-H446细胞中ZEB2的mRNA和蛋白表达水平明显降低(P<0.01),细胞增殖、迁移和侵袭能力均显著下降(P<0.05或P<0.01),促EMT蛋白表达减少,而同时过表达ZEB2能够逆转上述影响。体内实验中,miR-9过表达组移植瘤体积、重量均明显低于对照组(P<0.05或P<0.01)。miR-9组裸鼠肿瘤组织中和ZEB2蛋白的表达均较对照组明显降低(P<0.01)。结论:miR-9通过靶向调控ZEB2从而抑制SCLC细胞的生物学行为以及NCI-H446裸鼠移植瘤的生长。 相似文献
92.
93.
M.S. Iqbal G. Vashisht R. McMenemin P. Atherton F. McDonald T. Simmons A. Bradshaw J. Kovarik H. Turnbull L. Dodd P. Mulvenna A. Greystoke 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):e1-e10
Aims
Concomitant chemoradiation is the standard of care in patients with inoperable non-small cell lung cancer. The purpose of this study was to analyse the survival outcome and toxicity data of using hypofractionated chemoradiation.Materials and methods
One hundred patients were treated from June 2011 to November 2016. Treatment consisted of 55 Gy in 20 daily fractions concurrently with split-dose cisplatin vinorelbine chemotherapy over 4 weeks followed by two cycles of cisplatin vinorelbine only. Survival was estimated using Kaplan–Meier and Cox regression was carried out for known prognostic factors. A systematic search of literature was conducted using Medline, Embase and Cochrane databases and relevant references included.Results
In total, 97% of patients completed radiotherapy and 73% of patients completed all four cycles of chemotherapy. One patient died of a cardiac event during consolidative chemotherapy. There were two cases of grade 4 toxicities (one sepsis, one renal impairment). Grade 3 toxicities included nausea/vomiting (17%), oesophagitis (15%), infection with neutropenia (12%) and pneumonitis (4%). Clinical benefit was seen in 86%. Two-year progression-free survival and overall survival rates were 49% and 58%, respectively. The median progression-free survival and overall survival were 23.4 and 43.4 months, respectively. The only significant prognostic factor was the number of chemotherapy cycles received (P = 0.02). The systematic review identified 13 relevant studies; a variety of regimens were assessed with variable reporting of outcomes and toxicity but with overall an improvement in survival over time.Conclusion
Our experience compared with the original phase II trial showed improved treatment completion rates and survival with acceptable morbidity. With appropriate patient selection this regimen is an effective treatment option for locally advanced non-small cell lung cancer. This study helps to benchmark efficacy and toxicity rates while considering the addition of new agents to hypofractionated concurrent chemoradiotherapy. The agreement of a standard regimen for assessment in future trials would be beneficial. 相似文献94.
目的:观察非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)患者自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)术后应用重组人α-2b干扰素(α-2b IFN)进行早期干预治疗的临床疗效。方法:选取18例行ASCT的NHL患者为研究对象,移植前疾病评估均未达到完全缓解(complete remission,CR),试验组血象恢复后给予IFN 3 000 000 U次/隔日干预治疗,3个月后停用;对照组未行干扰素干预治疗,分析总体疗效及两组对比的生存情况。结果:随访中位时间为34(10~50)个月,患者中位生存时间为37(31~45)个月,3年总体无进展生存(progressive free survival,PFS)、总生存(overall survivial,OS)分别为54.7%、66.8%。ASCT后试验组1年内无疾病复发,2年内复发率为12.5%;对照组1年内复发率为20%,2年内复发率为30%。结论:NHL患者在ASCT后给予重组人α-2b IFN早期干预治疗,患者耐受性好,可能降低移植后早期复发率。 相似文献
95.
96.
目的:探讨五色培元固本膏对维持性血液透析(MHD)患者细胞免疫功能的影响。方法:90例MHD患者随机分为对照组和治疗组,两组血透方法相同。对照组给予一般治疗及血透治疗,治疗组在对照组基础上口服五色培元固本膏,连续治疗3个月; 20例健康志愿者作为正常组,三组观察时间均为3个月。治疗前后用流式细胞技术检测各组T细胞亚群表达水平,酶联免疫吸附法检测各组白介素-2(IL-2)和可溶性白介素-2受体(sIL-2R)蛋白表达水平。结果:治疗前与正常组比较,对照组与治疗组CD4+、CD4+/CD8+和IL-2表达水平均明显下降,CD8+和sIL-2表达水平均上升,差异有统计学意义(P<0.05)。治疗后,与对照组相比较,治疗组CD4+、CD4+/CD8+、IL-2表达水平明显升高,CD8+和sIL-2表达水平均降低,差异有统计学意义(P<0.05)。治疗组相较正常组CD4+T淋巴细胞、CD4+/CD8+、IL-2表达水平,差异无统计学意义(P>0.05),CD8+、sIL-2表达水平升高。结论:五色培元固本膏调节T淋巴细胞和IL-2表达改善MHD的细胞免疫功能。 相似文献
97.
98.
James I. Geller MD Joseph G. Pressey MD Malcolm A. Smith MD Rachel A. Kudgus PhD Mariana Cajaiba MD Joel M. Reid PhD David Hall PhD Donald A. Barkauskas PhD Stephen D. Voss MD Steve Y. Cho MD Stacey L. Berg MD Jeffrey S. Dome MD PhD Elizabeth Fox MD Brenda J. Weigel MD 《Cancer》2020,126(24):5303-5310
99.
Yu-Tzu Chan Alan C.-Y. Lai Ruey-Jen Lin Ya-Hui Wang Yi-Ting Wang Wen-Wei Chang Hsin-Yi Wu Yu-Ju Lin Wen-Ying Chang Jen-Chine Wu Jyh-Cherng Yu Yu-Ju Chen Alice L. Yu 《International journal of cancer. Journal international du cancer》2020,146(6):1674-1685
G protein-coupled estrogen receptor-1 (GPER), a member of the G protein-coupled receptor (GPCR) superfamily, mediates estrogen-induced proliferation of normal and malignant breast epithelial cells. However, its role in breast cancer stem cells (BCSCs) remains unclear. Here we showed greater expression of GPER in BCSCs than non-BCSCs of three patient-derived xenografts of ER−/PR+ breast cancers. GPER silencing reduced stemness features of BCSCs as reflected by reduced mammosphere forming capacity in vitro, and tumor growth in vivo with decreased BCSC populations. Comparative phosphoproteomics revealed greater GPER-mediated PKA/BAD signaling in BCSCs. Activation of GPER by its ligands, including tamoxifen (TMX), induced phosphorylation of PKA and BAD-Ser118 to sustain BCSC characteristics. Transfection with a dominant-negative mutant BAD (Ser118Ala) led to reduced cell survival. Taken together, GPER and its downstream signaling play a key role in maintaining the stemness of BCSCs, suggesting that GPER is a potential therapeutic target for eradicating BCSCs. 相似文献
100.
Ruby Del Risco Kollerud Hege S. Haugnes Bjørgulf Claussen Magne Thoresen Per Nafstad James M. Farnham Karl G. Blaasaas Øyvind Næss Lisa A. Cannon-Albright 《International journal of cancer. Journal international du cancer》2020,147(6):1604-1611
Similar family-based cancer and genealogy data from Norway and Utah allowed comparisons of the incidence of testicular cancer (TC), and exploration of the role of Scandinavian ancestry and family history of TC in TC risk. Our study utilizes data from the Utah Population Database and Norwegian Population Registers. All males born during 1951–2015 were followed for TC until the age of 29 years. A total of 1,974,287 and 832,836 males were born in Norway and Utah, respectively, of whom 2,686 individuals were diagnosed with TC in Norway and 531 in Utah. The incidence per year of TC in Norway (10.6) was twice that observed in Utah (5.1) for males born in the last period (1980–1984). The incidence rates of TC in Utah did not differ according to the presence or absence of Scandinavian ancestry (p = 0.669). Having a brother diagnosed with TC was a strong risk factor for TC among children born in Norway and Utah, with HR = 9.87 (95% CI 5.68–17.16) and 6.02 (95% CI 4.80–7.55), respectively; with even higher HR observed among the subset of children in Utah with Scandinavian ancestry (HR = 12.30, 95% CI 6.78–22.31). A clear difference in TC incidence among individuals born in Norway and descendants of Scandinavian people born in Utah was observed. These differences in TC rates point to the possibility of environmental influence. Family history of TC is a strong risk factor for developing TC in both populations. 相似文献